Zacks Company Profile for Apellis Pharmaceuticals, Inc. (APLS : NSDQ) |
|
|
|
Company Description |
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States.
Number of Employees: 476 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $44.81 |
Daily Weekly Monthly
 |
20 Day Moving Average: 1,152,715 shares |
Shares Outstanding: 106.52 (millions) |
Market Capitalization: $4,773.25 (millions) |
Beta: 1.63 |
52 Week High: $73.00 |
52 Week Low: $27.50 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-11.91% |
-0.80% |
12 Week |
3.42% |
13.68% |
Year To Date |
-5.22% |
14.95% |
|
|
|
|
|
|
|
General Corporate Information |
Officers
Cedric Francois - President; Chief Executive Officer and Director
Timothy E. Sullivan - Chief Financial Officer and Treasurer
Jim Chopas - Vice President; Corporate Controller and Chief Acc
Gerald Chan - Director
A. Sinclair Dunlop - Director
|
|
Peer Information
Apellis Pharmaceuticals, Inc. (CORR.)
Apellis Pharmaceuticals, Inc. (RSPI)
Apellis Pharmaceuticals, Inc. (CGXP)
Apellis Pharmaceuticals, Inc. (BGEN)
Apellis Pharmaceuticals, Inc. (GTBP)
Apellis Pharmaceuticals, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 03753U106
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
|
|
Share - Related Items
Shares Outstanding: 106.52
Most Recent Split Date: (:1)
Beta: 1.63
Market Capitalization: $4,773.25 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-1.50 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-5.58 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 7.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: 19.28% |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/08/22 |
|
|
|
|